Insadol
MarketedInsadol, an over-the-counter medicine brand for gum disease.
A total healthcare company that makes prescription drugs, over-the-counter medicines such as Insadol and Pansidil, and healthcare and cosmetics brands such as Centellian24.
Insadol, an over-the-counter medicine brand for gum disease.
Urescotine, an improved drug for benign prostatic hyperplasia combining dutasteride and tadalafil; it held a 76.3% share of its same-ingredient combination market as of June 2026 and is licensed to FAES FARMA of Spain for 13 Latin American countries.
Dermocosmetics brand led by Madeca Cream, which has expanded distribution to Costco, Ulta Beauty and Nordstrom stores in the U.S.
In-house long-acting injectable platform based on microsphere technology; it underlies Lorelin Depot, a prostate cancer drug the company developed in 1999, and Phase 3 results for the three-month Lorelin Depot 11.25mg have been presented abroad.
Central R&D Center founded in 1989 and located at the Gyeonggi Bio-Center in Suwon, Gyeonggi-do; using its formulation technology it developed products such as Lorelin Depot, Pofol and Hyalon in-house.
Centellian24 entered Costco, Ulta Beauty and Nordstrom in the U.S. in succession.
Exhibited with its own booth for the fifth straight year at CPHI Worldwide 2026 in Milan, Italy, in October 2026, presenting its DK-LADs long-acting injectable platform and holding about 300 business meetings.
Announced a plan to change its corporate name to DK Centellian to expand globally and into health and beauty, with an extraordinary general meeting scheduled for 2026-11-27 to amend the articles of incorporation.
Official role guide
Observed 2026-10-25
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.